🧬 Doug Drysdale - Cybin - Part 4 | The Challenges of Running a Public Company | Transforming Psychiatric Treatments Through Psychedelic Compounds | Developing Breakthrough Therapies in Depression & Anxiety

episode

The Biotech Startups Podcast not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Busting Brain Myths: TikTok's Viral Neuroscientist 11 min · 24 Sep 2026 · Today with David McCullagh

We Investigated the Christian "Scam" Fronted by Tim Tebow 1h 17m · 24 Sep 2026 · Pablo Torre Finds Out

Trump threatens Iran in fiery UN speech. What's next? 14 min · 24 Sep 2026 · The Excerpt

Dolly Parton library at risk of closure 5 min · 24 Sep 2026 · Today with David McCullagh

Have schoolchildren forgotten how to handwrite? 16 min · 24 Sep 2026 · Today with David McCullagh

Iran Addresses the World & Inside CA’s Welfare Scandal | 9.24.26 19 min · 24 Sep 2026 · Morning Wire

Report any issue

Source

Recorded05 Sep 2024

Publisherfeeds.fame.so ↗

Handlerec:3386522

Show notes

Part 4 of 4. My guest for this week’s episode is Doug Drysdale, CEO at Cybin. Cybin is a clinical-stage biopharma company on a mission to create safe and effective psychedelic-based therapeutics. Doug is an experienced investor, Corporate Director and CEO, who has chaired the Board of a NASDAQ-listed company and, as a CEO for the past 12 years, has built and turned around 3 pharma companies. During his 30+ years of experience in the healthcare sector, he has formed cohesive management teams, recruited board members, completed 16 corporate acquisitions across three continents and has raised and invested around $4 billion of both public and private capital.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in